Failure to complete the first phase of Brexit negotiations is costing UK pharmaceutical companies "an enormous amount of money", industry representatives have warned http://www.theneweuropean.co.uk/top-stories/pharmaceutical-industry-brexit-regulations-1-5308539 https://t.co/NIS79IbJfZ
